Pacira Pharmaceuticals (PCRX) Raised to Hold at ValuEngine
Pacira Pharmaceuticals (NASDAQ:PCRX) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
A number of other research analysts have also commented on the company. Zacks Investment Research lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. BidaskClub lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. Wedbush restated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, January 5th. HC Wainwright set a $55.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, January 4th. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, January 4th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $49.00.
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) traded down $0.73 during midday trading on Wednesday, hitting $41.50. The company had a trading volume of 1,031,870 shares, compared to its average volume of 712,847. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1,683.66, a price-to-earnings ratio of -31.68 and a beta of 2.20. Pacira Pharmaceuticals has a twelve month low of $29.81 and a twelve month high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.15. The business had revenue of $67.30 million during the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. Pacira Pharmaceuticals’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 earnings per share. equities analysts anticipate that Pacira Pharmaceuticals will post -0.85 EPS for the current year.
In other news, SVP James B. Jones sold 850 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $41.11, for a total transaction of $34,943.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the acquisition, the director now directly owns 6,795 shares of the company’s stock, valued at approximately $282,672. The disclosure for this purchase can be found here. Insiders have sold 98,960 shares of company stock valued at $3,868,341 over the last quarter. Corporate insiders own 6.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in PCRX. Schwab Charles Investment Management Inc. grew its holdings in shares of Pacira Pharmaceuticals by 8.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 178,700 shares of the company’s stock worth $8,524,000 after purchasing an additional 13,973 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Pacira Pharmaceuticals by 3.5% during the second quarter. Rhumbline Advisers now owns 49,203 shares of the company’s stock worth $2,347,000 after purchasing an additional 1,672 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Pacira Pharmaceuticals by 135.6% during the second quarter. SG Americas Securities LLC now owns 6,395 shares of the company’s stock worth $305,000 after purchasing an additional 3,681 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Pacira Pharmaceuticals by 5.6% during the second quarter. Bank of New York Mellon Corp now owns 218,087 shares of the company’s stock worth $10,403,000 after purchasing an additional 11,652 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Pacira Pharmaceuticals by 5.3% during the second quarter. Legal & General Group Plc now owns 12,985 shares of the company’s stock worth $620,000 after purchasing an additional 653 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: “Pacira Pharmaceuticals (PCRX) Raised to Hold at ValuEngine” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/14/pacira-pharmaceuticals-pcrx-raised-to-hold-at-valuengine.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.